GlassScriptPhysician profile
Carmante Extra
NPI 1356702997
$4,629.88
in general payments reported to CMS, 2019-2025
23 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $671 · 2022: $199 · 2023: $516 · 2024: $439 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911 · Honoraria: $980 · Travel and Lodging: $770 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.11 |
| Honoraria | $980.00 |
| Travel and Lodging | $769.63 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,262.47 | 2025 | Cabometyx |
| Amgen INC. | $316.92 | 2021-2024 | Lumakras, Blincyto, Neulasta |
| Ipsen Biopharmaceuticals, INC | $213.20 | 2021-2024 | Somatuline Depot, Onivyde |
| Incyte Corporation | $192.05 | 2021-2023 | Pemazyre |
| Daiichi Sankyo INC. | $182.86 | 2022 | |
| Dendreon Pharmaceuticals LLC | $145.38 | 2023 | Provenge |
| Deciphera Pharmaceuticals INC. | $143.18 | 2025 | Qinlock |
| Janssen Biotech, INC. | $140.31 | 2021-2023 | Darzalex |
| Pfizer INC. | $124.91 | 2024 | |
| Gilead Sciences, INC. | $113.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $113.44 | 2025 | Opdivo |
| Foundation Medicine, INC. | $107.79 | 2021 | |
| Puma Biotechnology, INC. | $105.76 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $101.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $88.56 | 2021-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $76.24 | 2025 | Carvykti |
| Emd Serono, INC. | $65.33 | 2022-2023 | Bavencio |
| Tersera Therapeutics LLC | $38.35 | 2024 | Zoladex |
| Beone Medicines USA, INC. | $25.92 | 2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $23.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.84 | 2021 | |
| Aadi Bioscience, INC. | $14.95 | 2023 | Fyarro |
| Glaxosmithkline, LLC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmante Extra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.